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Purpose: To investigate the complement factor H related 5 (CFHR5) gene, encoding a member of the complement factor
H family, for the presence of genetic polymorphisms or mutations associated with age-related macular degeneration
(AMD).
Methods: We screened 639 unrelated patients with AMD and 663 age-matched normal controls using direct genomic
sequencing of the ten coding exons, along with the immediately flanking intronic DNA. The pathologic impact of the
identified sequence variants were analyzed by computational methods using PolyPhen and PMut algorithms.
Results: We identified five heterozygous sequence changes in CFHR5. Asp169Asp had a minor allele frequency of
0.001% in patients and 0.014% in controls (p<0.0001), while Arg356His had a minor allele frequency of 0.016% in patients
and 0.007% in controls. Val379Leu, Met514Arg, and Cys568Ter were found only in normal controls. In silico analysis
predicted Arg356His and Val379Leu to be neutral and benign. Met514Arg was predicted to be pathological and damaging
to the function of the CFHR5 protein.
Conclusions: No definitive pathogenic CFHR5 mutations have been found in any of 639 unrelated patients with AMD,
indicating that sequence variations in CFHR5 do not play a major role in determining AMD susceptibility. However, our
findings suggest a possible protective role for Asp169Asp. Further studies of different and larger populations of patient
and control samples will be required to address this observation.
Age-related macular degeneration (AMD) is the leading
cause  of  irreversible  visual  loss  in  the  elderly  Western
population over the age of 60 [1]. AMD is a progressive
disorder  of  the  photoreceptor-retinal  pigment  epithelium
(RPE)-Bruch’s  membrane-choriocapillaris  complex.  AMD
typically  starts  with  a  few  macular  drusen,  the
lipoproteinaceous extracellular deposits localized between the
RPE and Bruch’s membrane, which is considered to be a
major  risk  factor  for  developing  the  disease.  However,
continued drusen evolution can lead to geographic atrophy,
choroidal neovascularization, and irreversible vision loss in
the later stages [1]. AMD is a complex, multifactorial disease
associated with environmental, dietary, and genetic factors.
Substantial evidence indicates that AMD has a strong genetic
component,  including  the  recent  discoveries  of
polymorphisms in genes involved in the regulation of the
immune-mediated  complement  pathway  including
complement  factor  H  (CFH),  complement  factor  B,
complement  component  2,  and  complement  component  3
(C3)  [2–7].  The  nonsynonymous  C  versus  T  nucleotide
polymorphism in the CFH gene, substituting histidine for
tyrosine at position 402 (Y402H), has been identified as the
most significant risk factor for developing AMD.
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Several regulators of complement activation, including
CFH,  lie  in  a  gene  cluster  and  have  been  mapped  to
chromosome  1q32.  An  evaluation  of  AMD  genome-wide
scans  reveals  that  the  strongest  linkage  to  AMD  is  on
chromosome  1q25–32  [8].  This  array  includes  genes  that
encode  the  seven  proteins  in  the  CFH  family  (Figure  1).
Structurally, these proteins are similar, each being built on a
motif of distinct functional domains typical of the regulators
of  complement  activation  called  short  consensus  repeats
(SCRs). The interacting partners with some of these SCRs
include C reactive protein (CRP), C3b, and heparin [9]. CFH-
like 1 (CFHL1) is a splice isoform of CFH, while complement
factor H-related proteins 1–5 (CFHR1–5) are each encoded
by a unique gene (CFHR1–5). The SCRs of CFHR1–5 are
similar to some of the SCRs in CFH [10].
Within the CFH family, the most recently discovered
component  is  CFHR5.  CFHR5,  which  shows  the  highest
similarity to CFH, has nine SCRs, with the first two being
similar to SCRs 6 and 7 of CFH and therefore having CRP
and heparin binding properties [10]. SCRs 3–7 of CFHR5 are
homologous to SCRs 10–14 of CFH, and SCRs 8–9 show
homology to the C3b binding domain of CFH in SCRs 19 and
20. CFHR5 is the only CFHR protein that, like CFH, possesses
cofactor activity leading to the inactivation of C3b. CFHR5
binds to human C3b in a dose-dependent manner [11–13]. The
complement regulatory activity of CFHR5 has been proposed
to rely upon its recruitment to sites of tissue damage by CRP
[12].
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731As mentioned, several studies have implicated specific
allele variants of CFH with the development of AMD. In
addition,  a  replication  study  on  the  NEI  dbGAP  single
nucleotide polymorphisms (SNPs) derived from the genome-
wide association study on the Age-Related Eye Disease Study
(AREDS)  patient  cohort  demonstrates  that  many  variants
located  in  tandem  on  1q32,  including  several  in  CFH,
CFHR2, CFHR4, and CFHR5, were significantly associated
with AMD risk [14].
Risk alleles in CFH have also been reported in patients
with  two  different  forms  of  kidney  disease,
membranoproliferative  glomerulonephritis  type  II  (MPGN
II), and hemolytic uraemic syndrome (HUS) [10,15]. MPGN
II  is  a  renal  disease  characterized  by  mesangial
hypercellularity  and  an  accumulation  of  electron-dense
material  in  the  lamina  densa  of  the  glomerular  basement
membrane. MPGN II causes chronic renal dysfunction that
can  progress  to  end  stage  renal  disease.  HUS  is  a  rare
syndrome  characterized  by  the  triad  of  microangiopathic
hemolytic anemia, thrombocytopenia, and acute renal failure.
It is the most common cause of acute renal failure in children.
Patients with MPGN II, HUS, and AMD segregate several of
the same CFH risk alleles [10,15]. Patients with MPGN II also
develop ocular drusen that are clinically indistinguishable
from drusen that form in AMD [16,17]. The sole difference
between these two types of drusen is the age of onset; drusen
in MPGN II develop early around the second decade of life,
whereas drusen in AMD are found in the fifth or sixth decade
of life. Moreover, cases have been described where MPGN II
patients develop AMD later in life [18]. Recently, SNPs in
CFHR5 have been associated with both MPGN II and HUS,
suggesting an important role for CFHR5 in the protection of
cells against complement activation at least in the glomeruli
of kidneys, although its exact functional properties remain
unknown [10,15].
The possible relationship between MPGN II and AMD
as diseases that share a genetic association with complement
genes as well as complement proteins characteristic of their
dense deposits motivated us to hypothesize that like CFH,
CFHR5  could  predispose  to  the  development  of  AMD.
Furthermore, recent evidence indicates that variants in CFHR
genes may confer risk for AMD. To evaluate this possibility,
we screened a large number of AMD cases and age-matched
controls  for  genetic  abnormalities  in  CFHR5  that  are
associated with AMD.
METHODS
Ascertainment of patients: This study conformed to the tenets
of  the  Declaration  of  Helsinki  and  was  approved  by  the
Internal Review Boards of the Cleveland Clinic Foundation.
All blood samples were obtained after informed consent was
secured. We collected a total of 639 index cases with AMD
that were diagnosed through ophthalmologic examination and
were subcategorized into one of four experimental groups
using the criteria defined by the AREDS study [19]. Briefly,
AMD Category 1 subjects had five or less small drusen/eye
(<63 µm) and visual acuity of 20/30 or better in both eyes.
AMD Category 2 patients exhibited early-stage disease with
multiple small drusen, single or nonextensive intermediate
drusen (63–124 μm), RPE pigmentary abnormalities, or any
combination of these, in one or both eyes and visual acuity of
20/30  or  better  in  both  eyes.  AMD  Category  3  patients
exhibited mid-stage disease with at least one eye having visual
acuity  20/30  or  better  and  one  large  drusen  (125  μm),
extensive intermediate drusen or geographic atrophy that did
not involve the macula or any combination of these. Category
3  patients  lacked  advanced  AMD  in  either  eye.  AMD
Category 4 patients exhibited advanced AMD with substantial
choroidal neovascularization or geographic atrophy involving
the macula in one or both eyes.
Figure 1. Schematic representation of
the genomic structures of the genes in
the CFH gene family. The CFH family
is composed of several distinct proteins
that lie in a gene cluster on chromosome
1.  Structurally,  these  proteins  are
similar.  They  each  contain  several
functional  domains  called  short
consensus  repeats  (SCRs),  which  are
drawn as ovals in this illustration. The
interacting proteins for some of these
SCRs  have  been  determined  and  are
shown  at  the  top.  Abbreviations:  C
reactive protein (CRP); heparin (Hep).
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732Of the 639 patients, 26 were defined as Category 1 AMD,
43  were  Category  2,  90  were  Category  3  and  480  were
Category 4. AMD Category 1 consisted of 12 males and 14
females.  AMD  Category  2  consisted  of  12  males  and  31
females.  AMD  Category  3  consisted  of  35  males  and  55
females and AMD Category 4 consisted of 88 males and 292
females.  629  patients  were  over  the  age  of  60  and  the
remaining 10 were over the age of 53. The age range was
between 53 and 105 with a mean age of 81.7.
A  total  of  663  unrelated  individuals  without  retinal
disease  as  diagnosed  by  ophthalmologic  examination  and
without a family history of retinal disease were used as normal
control subjects. In our control population, there were 298
males and 365 females. The age range was between 50 and
103 with a mean age of 70.3. Leukocyte nuclei were prepared
from the blood samples followed by DNA purification using
standard protocols.
Mutation screening: For mutation detection, PCR products
corresponding  to  the  complete  known  CFHR5  coding
sequence (accession number BC111773) were amplified from
genomic DNA and analyzed by direct genomic sequencing.
Ten primer pairs were designed to cover the ten coding exons
and adjacent intronic regions of CFHR5 and are listed in Table
1  along  with  the  PCR  conditions.  The  buffer  pH,  Mg2+
concentration,  annealing  temperature,  and  presence  or
absence of 10% dimethyl sulfoxide were tailored to each
primer pair to yield optimal amplification.
Unused primer molecules and dNTPs were removed from
the amplified PCR product by treating with ExoSAP-IT (USB,
Cleveland, OH) at 37 °C for 15 min and at 80 °C for 15 min
to inactivate the enzymes. Sequencing was performed using
2 μl of BigDye Terminator v1.1 cycle Ready Reaction Mix
(Applied  Biosystems,  Foster  City,  CA),  3  μl  of  BigDye
Terminator  v1.1  cycle  Sequencing  Buffer,  5  pmol  of
sequencing  primer  and  5  μl  of  ExoSAP-IT  purified  PCR
product  in  a  total  volume  of  20  μl.  Cycling  parameters
followed the manufacturer’s instructions. Unincorporated dye
terminators were removed using Performa DTR gel filtration
plates  (Edge  Biosystems,  Gaithersburg,  MD).  Sequencing
was  performed  using  an  ABI  3130xl  Genetic  Analyzer
(Applied Biosystems), and the collected data was analyzed
with SeqScape v2.5 software.
Computational  assessment  of  missense  mutations:  Two
sequence homology based programs were used to predict the
functional impact of missense changes identified in this study:
PolyPhen (Polymorphism Phenotyping,) and PMut. PolyPhen
structurally  analyzes  an  amino  acid  polymorphism  and
predicts  whether  that  amino  acid  change  is  likely  to  be
deleterious to protein function [20]. The prediction is based
on  the  position-specific  independent  counts  (PSIC)  score
derived from multiple sequence alignments of observations.
PolyPhen  scores  of  >2.0  indicate  the  polymorphism  is
probably damaging to protein function. Scores of 1.5–2.0 are
possibly damaging, and scores of <1.5 are likely benign. PMut
allows the accurate pathological prediction of single amino
acid mutations based on the use of neural networks [21].
Following the input of a reference sequence and the amino
acid substitution of interest, the algorithm provides an answer
and a reliability index. An output value >0.5 is predicted to be
a  pathological  mutation  and  a  value  <0.5  is  neutral.  The
reliability is considered good with a score of six and greater
and is highly reliable at the maximum score of nine.
TABLE 1. PCR CONDITIONS AND PRIMERS USED TO AMPLIFY CFHR5 IN THIS STUDY.
Exon Primers (3′-5′)
Annealing
temperature (°C)
Buffer
pH
MgCl2
(mM)
%
DMSO
Fragment
(bp)
1 F: GCAGATTTAAAGCAACACCACC 60 8.4 1 0 242
R: CCCCTTCAAATTATCCTCAGC
2 F: CTAGTGATTCATCGATGTAGCTC 52 8.4 1 10 370
R: TTTCCAGCTCCTCTGGTCATTGC
3 F: TGATGTCAGTTTTCAAAGTTTTCC 54 8.4 1 0 313
R: TAATTAGCAAAACTGAGAGAGTGG
4 F: GCACACATTAAATTTGTTTCTGCA 54 8.4 1.5 0 345
R: TACCACTTTGTCAGATTATAGATG
5 F: TAGTAACTCCACATTTTTCTATAC 50 8.4 1.5 0 301
R: TAAGTGCAAAGTAATAGTAACTGT
6 F: AATATTTTCAGAGTAAGCACTCAT 50 8.4 1.5 0 288
R: ACACTTTATACAATCCCAATCAAA
7 F: GTGATGTTGCTTAAAAGCATCAAAC 54 8.6 1.5 0 325
R: CTTGTAAAGAAGCAACAAGATCAAC
8 F: CCATTTTCCTGAAACACTACCCTA 52 8.4 1.5 0 377
R: TTGGGGTACAGTGCAACAGATTAG
9 F: AATTATTTGAATTTCCAGACACCT 50 8.4 1.5 0 375
R: GGGTTATTCTATGAAATTAGTCCA
10 F: GCAATTTCACTATTCTATGAAAGG 52 8.4 1.5 0 348
R: ACAGAATTGGCTACATAATGGCT
This table summarizes the PCR conditions and primers used to amplify CFHR5 in this study.
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Weinberg equilibrium. A two-tailed Fisher’s exact test was
used for comparisons of allele frequencies.
RESULTS AND DISCUSSION
In  the  present  study,  we  analyzed  the  CFHR5  gene  for
mutations  in  patients  with  AMD  to  search  for  sequence
changes that might be associated with disease. Because of the
strong  homology  between CFH  and  CFHR5,  the possible
relationship between MPGN II and AMD as diseases that
share a genetic association with complement genes, and recent
evidence of variants in CFHR genes that may predispose an
individual to AMD, we considered this gene a candidate for
AMD.
Five SNPs in CFHR5 have been associated with MPGN
II, a renal disease that shares genetic association with genes
associated  with  AMD  [15].  These  include  one
nonsynonymous SNP (exon 2 P46S), two promoter SNPs
(−249T→C  and  −20T→C),  and  two  intronic  SNPs
(IVS1+75T→A and IVS2+58C→T). Allele frequencies of
three  (exon  2  P46S,  −249T→C  and  −20T→C)  were
significantly  different  between  patients  and  controls.  We
postulate that the two SNPs in the promoter region could affect
transcription, one by removing a binding site for C/EBPβ and
the other by adding a GATA-1 binding site. The missense
change  proline  to  serine  in  exon  2  encodes  a  domain
homologous to SCR6 of CFH, which is integral to heparin and
C  reactive  protein  binding,  therefore  possibly  affecting
complement activation and control. Our mutation analysis
screened for all five of these SNPs in 639 patients with AMD
and did not identify any of these genetic changes in our patient
population.
Five CFHR5 variants different from those described in
MPGN II patients have been associated with HUS, a renal
disease that also shares genetic association with AMD [10].
These variants include four missense changes (Leu66Phe,
Lys126Asn,  Arg338His,  and  Met496Arg)  and  one  stop
mutation (Asn197Ter). Our mutation analysis screened for all
five variants in 639 patients with AMD and did not identify
any of these genetic changes.
Instead,  we  identified  five  different  heterozygous
sequence changes in CFHR5 (Table 2); however, none appear
to  be  definitively  associated  with  disease.  No  significant
deviations from Hardy–Weinberg equilibrium for any of the
variants studied were observed. Two variants (Asp169Asp
and Arg356His) were identified in AMD patients and normal
controls while the other three (Val379Leu, Met514Arg, and
Cys568Ter) were found only in controls.
In exon 7, Arg356His was found in 20 patients: 15 from
Category 4, two from Category 3, and three from Category 2.
It was also identified in normal controls. The minor allele
frequency for this sequence change is 0.016% in patients and
TABLE 2. SEQUENCE ALTERATIONS IDENTIFIED IN CFHR5.
Exon Sequence change                     Protein change
                       Allele frequency
AMD patients
Allele frequency                   
4 GAC→GAT Asp169Asp 1/1278=0.001% 18/1326=0.014% p<0.0001
7 CGT→CAT Arg356His 20/1278=0.016% 9/1326=0.007% p=0.039
7 GTA→CTA Val379Leu 0/1278=0.0% 3/1326=0.002% p=0.250
10 ATG→AGG Met514Arg 0/1278=0.0% 1/1326=0.001% p=1.000
10 TGT→TGA Cys568Ter 0/1278=0.0% 3/1326=0.002% p=0.250
This table summarizes the sequence changes identified in CFHR5 in this study.
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normals                          p value
The Asp169Asp synonymous SNP was identified in one
Category 4 AMD patient, yielding a minor allele frequency of
0.001%. Asp169Asp had an allele frequency of 0.14% in
normal controls and appeared to be a common variant as it is
present  in  the  NCBI  SNP  database  (rs34533956).  This
isocoding change does not alter the predicted wild-type amino
acid sequence nor is it predicted to create or destroy splice
donor  or  acceptor  sites  based  on  splice-site  prediction
software  by  neural  network  available  at  the  Berkeley
Drosophila Genome Project; however, it warrants additional
consideration. Our data indicate that the mutant T allele is less
frequent in AMD patients as compared to normal controls
(p<0.0001), suggesting that this variant is associated with a
reduced risk for developing AMD. Whether this variant is a
protective allele or is simply linked to a different nearby gene
variant remains to be determined. If protective, it is possible
that  this  sequence  change  exerts  its  effects  by  improving
mRNA  stability  or  by  effecting  the  splicing  of  RNA
transcripts  which  is  thought  to  be  partly  regulated  by
sequences  embedded  within  exons  [22,23].  Silent
polymorphisms within genes have been shown to influence
the quality and fidelity of mRNA metabolism such as the rate
of  gene  transcription,  the  stability  of  the  mRNA,  or  the
quantity and activity of the resulting protein [24]. Sequences
known  to  affect  RNA  splicing  include  exonic  splicing
enhancers  or  exon  splicing  silencers,  which  consist  of
common motifs of only 6–8 bases and activate nearby splice
sites and promote the inclusion or exclusion of exons in which
they reside [25]. In addressing our observation, additional
studies  of  different  and  larger  populations  of  patient  and
control samples will be required as well as functional studies
concerning this specific sequence change.0.007%  in  normal  controls  (p=0.039).  Arg356His  also
appears to be a common variant and is present in the NCBI
SNP database (rs35662416). In silico analysis using PolyPhen
predicted this variant to be benign. A small difference (1.190)
was noted in PSIC scores between the allelic variants. PMut
analysis also predicted Arg356His to be neutral (output value
of 0.3) with good reliability (score of 5).
Two missense changes (Val379Leu and Met514Arg) and
one stop mutation (Cys568Ter) were found heterozygously
only in controls and not in any category of AMD patients.
Val379Leu had a minor allele frequency of 0.002%. Both
PolyPhen and PMut analysis predicted Val379Leu to be a
neutral (output value of 0.3) and benign substitution with high
reliability (score of 4). The rare variant Met514Arg warrants
consideration. It was identified in one female control aged 79,
yielding a minor allele frequency of 0.001%. Interestingly,
PolyPhen  predicted  this  missense  change  to  be  probably
damaging. A large difference (2.852) was calculated in PSIC
scores between the allelic variants. This difference indicates
that the observed substitution is rarely or never observed in
the CFH protein family and is predictive of a hydrophobicity
charge  change  at  a  buried  site  within  the  protein.  PMut
analysis also predicted Met514Arg to be pathological (output
value of 0.9) with very high reliability (score of 7). It is
possible that this mutation affects the function of CFHR5 by
changing the neutral, nonpolar side chain of methionine to the
basic, positively charged  side chain  of  arginine.  In fact, the
location of this mutation is embedded within the C-terminal
region of the protein that binds to C3b and Heparin. The stop
mutation Cys568Ter was identified in three normal control
individuals  aged  58,  61,  and  85,  yielding  a  minor  allele
frequency of 0.002%. This mutation occurs in the penultimate
amino acid of the CFHR5 protein and therefore may not affect
protein function.
Our results indicate that sequence variations in CFHR5
are  extremely  rare  in  patients  with  AMD.  Five  sequence
variations were identified with very low frequency. All are
likely to be nonpathogenic polymorphisms as two are known
SNPs and three were identified only in normal controls. The
nonsynonymous  missense  changes  (Arg356His  and
Val379Leu)  were  consistently  estimated  to  be  neutral  or
benign by computational analysis. However, the Met514Arg
missense  change  warrants  additional  consideration.  Both
bioinformatic  algorithms  predicted  this  mutation  to  be
pathological  and  damaging  to  the  function  of  CFHR5.
Although this mutation was identified in a single age-matched
control  individual,  she  should  be  evaluated  by  an
ophthalmologist  for  the  possible  development  of  AMD.
Whether this variant is pathological remains to be determined.
Asp169Asp also deserves consideration. The frequency of the
mutant allele was significantly higher in controls than in all
AMD  patients  (p<0.0001),  suggesting  that  this  variant  is
acting to decrease susceptibility to AMD. In addressing these
observations,  further  studies  of  different  and  larger
populations of patient and control samples will be required.
It is possible that SNPs associated with AMD as well as
pathogenic mutations in CFHR5 may exist outside of the
coding exons and flanking intron splice sites screened in this
study. It is not unreasonable to consider noncoding DNA
variants to underlie a complex disease phenotype, such as
AMD, as complex conditions are likely to be caused by several
common variants across a variety of loci, each responsible for
only minor effects. These minor effects may be the result of
DNA variants in the noncoding regulatory elements, which
may be capable of subtle changes in gene expression in a tissue
or developmental stage-specific manner. Finally, it is also
possible that pathogenic mutations occur in CFHR5 in a form
of  retinal  degeneration  not  included  in  our  patient  set.
Nonetheless, our results indicate that CFHR5 mutations or
polymorphisms are not definitively associated with AMD.
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